• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798

Introduction to 3-(1H-pyrazol-1-yl)cyclobutan-1-amine (CAS No. 2090620-55-4)

3-(1H-pyrazol-1-yl)cyclobutan-1-amine, with the CAS number 2090620-55-4, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a cyclobutane ring fused with a pyrazole moiety, making it a promising candidate for various therapeutic applications.

The molecular structure of 3-(1H-pyrazol-1-yl)cyclobutan-1-amine consists of a cyclobutane ring substituted with an amino group and a pyrazole ring. The pyrazole ring, known for its biological activity, is a five-membered heterocyclic aromatic compound containing two nitrogen atoms. The cyclobutane ring, on the other hand, is a four-carbon cyclic structure that imparts unique conformational properties to the molecule. These structural elements contribute to the compound's potential as a ligand for various biological targets.

Recent studies have highlighted the potential of 3-(1H-pyrazol-1-yl)cyclobutan-1-amine in the development of novel drugs. One notable area of research is its interaction with G protein-coupled receptors (GPCRs), which are key targets for many therapeutic agents. GPCRs play crucial roles in various physiological processes, including neurotransmission, hormone signaling, and immune responses. The ability of 3-(1H-pyrazol-1-yl)cyclobutan-1-amine to modulate GPCR activity has been explored in several preclinical studies, demonstrating its potential as a lead compound for drug discovery.

In addition to its interactions with GPCRs, 3-(1H-pyrazol-1-yl)cyclobutan-1-amine has shown promise in the treatment of neurological disorders. Preclinical studies have indicated that this compound can cross the blood-brain barrier and exhibit neuroprotective effects. Specifically, it has been shown to reduce oxidative stress and inflammation in neuronal cells, which are key factors in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

The pharmacokinetic properties of 3-(1H-pyrazol-1-yl)cyclobutan-1-amine have also been investigated to ensure its suitability for therapeutic use. Studies have demonstrated that this compound has favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It exhibits good oral bioavailability and a reasonable half-life, making it suitable for chronic administration. Furthermore, its low toxicity profile in animal models suggests that it is safe for further clinical evaluation.

Clinical trials are currently underway to evaluate the safety and efficacy of 3-(1H-pyrazol-1-yl)cyclobutan-1-amine in humans. Early-phase trials have shown promising results, with the compound demonstrating good tolerability and preliminary evidence of therapeutic benefit in patients with certain neurological conditions. These findings have paved the way for more advanced clinical studies to further validate its potential as a novel therapeutic agent.

In conclusion, 3-(1H-pyrazol-1-yl)cyclobutan-1-amine (CAS No. 2090620-55-4) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features and favorable pharmacological properties make it an attractive candidate for the development of new drugs targeting GPCRs and neurological disorders. Ongoing research and clinical trials will continue to elucidate its full therapeutic potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)